Samuel L Washington Iii

List of Publications by Citations

Source: https://exaly.com/author-pdf/3577058/samuel-l-washington-iii-publications-by-citations.pdf
Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

70 papers	488 citations	12 h-index	20 g-index
106 ext. papers	769 ext. citations	3.1 avg, IF	4.15 L-index

#	Paper	IF	Citations
70	Out-of-pocket fertility patient expense: data from a multicenter prospective infertility cohort. *Journal of Urology*, **2014**, 191, 427-32	2.5	70
69	Rapid Utilization of Telehealth in a Comprehensive Cancer Center as a Response to COVID-19: Cross-Sectional Analysis. *Journal of Medical Internet Research*, **2020**, 22, e19322	7.6	68
68	Transrectal ultrasonography-guided biopsy does not reliably identify dominant cancer location in men with low-risk prostate cancer. *BJU International*, **2012**, 110, 50-5	5.6	38
67	Management for prostate cancer treatment related posterior urethral and bladder neck stenosis with stents. *Journal of Urology*, **2011**, 185, 198-203	2.5	31
66	Impact of the United States Preventive Services Task Force VDVrecommendation on prostate cancer screening and staging. *Current Opinion in Urology*, **2017**, 27, 205-209	2.8	30
65	A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. *Drug Design, Development and Therapy*, **2010**, 4, 159-71	4.4	23
64	Web-Based Physician Ratings for California Physicians on Probation. *Journal of Medical Internet Research*, **2017**, 19, e254	7.6	20
63	Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer. *European Urology Oncology*, **2018**, 1, 386-394	6.7	14
62	Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US. *JAMA Network Open*, **2020**, 3, e2031349	10.4	14
61	The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations. *European Urology*, **2020**, 78, 335-344	10.2	13
60	Serial prostate biopsy and risk of lower urinary tract symptoms: results from a large, single-institution active surveillance cohort. *Urology*, **2014**, 83, 33-8	1.6	12
59	Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer. *Journal of Urology*, **2019**, 202, 696-701	2.5	12
58	Benign prostate glandular tissue at radical prostatectomy surgical margins. *Urology*, **2013**, 82, 154-9	1.6	9
57	Racial distribution of urology workforce in United States in comparison to general population. *Translational Andrology and Urology*, **2018**, 7, 526-534	2.3	9
56	Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer. *Clinical Genitourinary Cancer*, **2019**, 17, e461-e471	3.3	8
55	Social Determinants of Appropriate Treatment for Muscle-Invasive Bladder Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2019**, 28, 1339-1344	4	8
54	MRI-Based Prostate-Specific Antigen Density Predicts Gleason Score Upgrade in an Active Surveillance Cohort. *American Journal of Roentgenology*, **2020**, 214, 574-578	5.4	8

53	Post-Diagnostic Dietary and Lifestyle Factors and Prostate Cancer Recurrence, Progression, and Mortality. *Current Oncology Reports*, **2021**, 23, 37	6.3	8
52	Management of intermediate-risk prostate cancer with active surveillance: never or sometimes?. *Current Opinion in Urology*, **2017**, 27, 231-237	2.8	7
51	Health Care Delivery for Metastatic Hormone-sensitive Prostate Cancer Across the Globe. *European Urology Focus*, **2019**, 5, 155-158	5.1	7
50	Perspectives From Authors and Editors in the Biomedical Disciplines on Predatory Journals: Survey Study. *Journal of Medical Internet Research*, **2019**, 21, e13769	7.6	6
49	Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer. *Journal of Urology*, **2020**, 204, 1216-1221	2.5	5
48	The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. *Journal of Urology*, **2020**, 204, 1222-1228	2.5	5
47	Rapid Utilization of Telehealth in a Comprehensive Cancer Center as a Response to COVID-19		5
46	Disparities in fertility knowledge among women from low and high resource settings presenting for fertility care in two United States metropolitan centers. *Fertility Research and Practice*, **2020**, 6, 15	3	5
45	Automating the Capture of Structured Pathology Data for Prostate Cancer Clinical Care and Research. *JCO Clinical Cancer Informatics*, **2019**, 3, 1-8	5.2	5
44	Whom to Treat: Postdiagnostic Risk Assessment with Gleason Score, Risk Models, and Genomic Classifier. *Urologic Clinics of North America*, **2017**, 44, 547-555	2.9	4
43	Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer. *European Urology Oncology*, **2021**,	6.7	4
42	The Association Between Race and Frailty in Older Adults Presenting to a Nononcologic Urology Practice. *Urology*, **2019**, 127, 19-23	1.6	3
41	Current Use of Imaging after Primary Treatment of Prostate Cancer. *Journal of Urology*, **2015**, 194, 98-104	4.5	3
40	Acute Bladder Necrosis after Pelvic Arterial Embolization for Pelvic Trauma: Lessons Learned from Two Cases of Immediate Postembolization Bladder Necrosis. *Case Reports in Urology*, **2016**, 2016, 7594192	0.5	3
39	The Impact of Stone Multiplicity on Surgical Decisions for Patients with Large Stone Burden: Results from ReSKU. *Journal of Endourology*, **2019**, 33, 742-749	2.7	2
38	Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer. *European Urology*, **2020**, 78, 515-517	10.2	2
37	2285 THE COST OF MALE INFERTILITY CARE: HOW MUCH ARE PATIENTS SPENDING?. *Journal of Urology*, **2013**, 189,	2.5	2
36	Bladder cancer in patients younger than 40 years: outcomes from the National Cancer Database. *World Journal of Urology*, **2021**, 39, 1911-1916	4	2

35	What is the Impact of Racial Disparities on Diagnosis and Receipt of Appropriate Mental Health Care Among Urology Patients?. *European Urology Focus*, **2020**, 6, 1155-1157	5.1	2
34	A comparison of stage-specific all-cause mortality between testicular sex cord stromal tumors and germ cell tumors: results from the National Cancer Database. *BMC Urology*, **2020**, 20, 40	2.2	2
33	Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen. *Journal of Urology*, **2021**, 206, 706-714	2.5	2
32	MRI-based prostate specific antigen density predicts Gleason score upgrade in an active surveillance cohort.. *Journal of Clinical Oncology*, **2019**, 37, 107-107	2.2	1
31	Ultrasound-Guided Renal Access and Tract Dilation. *Videourology (New Rochelle, N Y)*, **2017**, 31,	0.9	1
30	How Often Does Magnetic Resonance Imaging Detect Prostate Cancer Missed by Transrectal Ultrasound?. *European Urology Focus*, **2021**, 7, 1268-1273	5.1	1
29	Race modifies survival benefit of guideline-based treatment: Implications for reducing disparities in muscle invasive bladder cancer. *Cancer Medicine*, **2020**, 9, 8310-8317	4.8	1
28	Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort. *Prostate*, **2021**, 81, 1009-1017	4.2	1
27	Active surveillance for intermediate-risk prostate cancer: yes, but for whom?. *Current Opinion in Urology*, **2019**, 29, 605-611	2.8	1
26	Influence of pelvic lymph node dissection and node-positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer. *Prostate*, **2021**, 81, 102-108	4.2	1
25	Liposomal Bupivacaine Decreases Postoperative Length of Stay and Opioid Use in Patients Undergoing Radical Cystectomy. *Urology*, **2021**, 149, 168-173	1.6	1
24	A Cross-Sectional Analysis of Barriers Associated With Non-Attendance at a Urology Telehealth Clinic in a Safety-Net Hospital. *Urology*, **2021**,	1.6	1
23	Active surveillance in intermediate-risk prostate cancer with PSA 10-20 ng/mL: pathological outcome analysis of a population-level database. *Prostate Cancer and Prostatic Diseases*, **2021**,	6.2	1
22	Mediators of Racial Disparity in the Use of Prostate Magnetic Resonance Imaging Among Patients With Prostate Cancer.. *JAMA Oncology*, **2022**,	13.4	1
21	The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer.. *Journal of Urology*, **2022**, 101097JU0000000000002420	2.5	0
20	Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate Cancer. *Journal of Urology*, **2021**, 101097JU0000000000002335	2.5	0
19	Urologic Cancer and the First Patterns of Metastasis **2022**, 587-592		0
18	Cystoscopic Evaluation of Bladder Leiomyoma. *Urology*, **2017**, 106, e1-e2	1.6	

17	Urinary Diversion for Incontinence and Voiding Dysfunction in Cancer Survivors: a Critical Review of the Literature. *Current Bladder Dysfunction Reports*, **2017**, 12, 167-173	0.4
16	Missed opportunity: An intersectional approach to disparities in long-term survival in bladder cancer.. *Journal of Clinical Oncology*, **2020**, 38, 476-476	2.2
15	Natural history of an immediately detectable PSA following radical prostatectomy: A description of a contemporary cohort.. *Journal of Clinical Oncology*, **2020**, 38, 356-356	2.2
14	Assessing focality of dominant tumor on serial biopsy in an active surveillance cohort: Implications for focal therapy.. *Journal of Clinical Oncology*, **2020**, 38, 352-352	2.2
13	Influence of node-positive disease after radical prostatectomy on biochemical recurrence and oncologic outcomes in men with prostate cancer.. *Journal of Clinical Oncology*, **2020**, 38, 306-306	2.2
12	Risk factors which predict biopsy upgrading over time in active surveillance for prostate cancer.. *Journal of Clinical Oncology*, **2020**, 38, 290-290	2.2
11	The Clinical Applications of Tissue Biomarkers in Prostate Cancer. *Società Internationale di Urologie Journal*, **2020**, 1, 23-29	0.1
10	Active Surveillance in African-Americans **2018**, 53-58	
9	Determinants of guideline-based treatment in patients with cT1 bladder cancer.. *Journal of Clinical Oncology*, **2018**, 36, e16518-e16518	2.2
8	Cribriform pattern, Genomic Prostate Score, and adverse pathology at radical prostatectomy in a cohort of prostate cancer patients initially on active surveillance.. *Journal of Clinical Oncology*, **2019**, 37, 88-88	2.2
7	18-year prostate cancer-specific mortality after prostatectomy, brachytherapy, external beam radiation therapy, hormonal therapy, or monitoring for localized prostate cancer.. *Journal of Clinical Oncology*, **2020**, 38, 300-300	2.2
6	Reply by Authors. *Journal of Urology*, **2020**, 204, 1221	2.5
5	Young patients with bladder cancer: Outcomes from the National Cancer Database.. *Journal of Clinical Oncology*, **2017**, 35, 380-380	2.2
4	Impact of histologic subtype on bladder cancer outcome.. *Journal of Clinical Oncology*, **2017**, 35, 391-391	2.2
3	Mediators of racial disparity in the use of prostate MRI.. *Journal of Clinical Oncology*, **2021**, 39, 6554-6554	2.2
2	EDITORIAL COMMENT. *Urology*, **2021**, 148, 209-210	1.6
1	EDITORIAL COMMENT.. *Urology*, **2022**, 162, 26	1.6